What's the purpose of this trial?

This goal of this Phase 1 clinical trial is to test how safe and effective belantamab mafodotin is when combined with bortezomib, lenalidomide, and dexamethasone. Researchers want to determine the safest and most effective dose of belantamab mafodotin, and study whether it can improve your myeloma when combined with the other study drugs.

This trial is currently open and accepting patients.

What will happen during the trial?

This trial is seeking approximately 144 patients. Patients will receive the study drugs over 21 or 28 day cycles and can continue to receive the study drugs as long as they are benefitting from them, don’t develop bad side effects, and their myeloma does not get worse.

While participating in this trial patients will need to have additional eye exams and screenings and are not allowed to wear contact lenses (except for bandage contact lenses if indicated). Patients will need to give themselves eye drops (artificial tears) each day as long as they are receiving belantamab mafodotin.

This trial will look at how patients react to and how the body uses belantamab mafodotin at different doses when taken together with bortezomib, lenalidomide and dexamethasone. We also want to know how the combination of these drugs affects your cancer. We will give patients in the trial different doses of belantamab mafodotin.  The other three drugs will be given at the doses allowed in the country where you are located.  The effects of the study drugs, both good and bad, will be studied.

There may be up to eight planned dose levels of belantamab mafodotin.

• Cycles 1-8 (21 days each)
  • Belantamab mafodotin will be given by intravenous infusion. Doses will be given as either a single (Day 1) or split dose (Day 1, 8)
  • Bortezomib will be given as a subcutaneous injection on days 1,4, 8, and 11.
  • Lenalidomide will be taken by mouth on days 1-14.
  • Dexamethasone will be taken by mouth on days 1, 2, 4, 5, 8, 9, 11 and 12.
• Cycles 9 onwards (28 days each)
  • Belantamab mafodotin will be given by intravenous infusion. Doses will be given as either a single (Day 1) or split dose (Day 1, 8)
  • Lenalidomide will be taken by mouth on days 1-21.
  • Dexamethasone will be taken by mouth on days 1, 8, 15, and 22.

If you have stopped study treatment and your multiple myeloma has not gotten worse, you will have one further follow up visit and will then stop the trial and receive another treatment prescribed by your study doctor.   You may choose to stop participating in this trial at any time. If your myeloma gets worse, or you develop bad side effects, researchers may remove you from the trial.

You may be able to join this trial if you:

The following criteria is a partial list of reasons why patients may be eligible to participate in this clinical trial. Further evaluation with a medical professional is required.

Additional Trial Information

Phase 1

Enrollment: 144 patients (estimated)